Common side effects of capmatinib (Touradida) and practical methods to alleviate them

Capmatinib (capmatinib) is an oral small molecule targeted drug, mainly used to treat patients with positive MET exon 14 skipping mutations in non-small cell lung cancer (NSCLC). As a MET receptor tyrosine kinase inhibitor, capmatinib can block the proliferation and metastasis signals of tumor cells, thereby delaying disease progression. However, like other targeted drugs, capmatinib may also cause certain adverse reactions while exerting its efficacy. Understanding its common side effects and scientific mitigation measures is particularly important for patients’ safe medication and long-term treatment.

Hematologically, capmatinib may cause anemia, neutropenia, or thrombocytopenia. Manifestations of anemia often include fatigue, paleness, palpitations, or shortness of breath; neutropenia may increase the risk of infection, and thrombocytopenia may lead to bleeding tendencies. For these hematological abnormalities, it is clinically recommended to monitor routine blood tests before and during treatment. Mild to moderate abnormalities can be intervened through rest, nutritional support, and, if necessary, oral or intravenous iron supplements, erythropoietin, etc. If there is a severe drop in blood cells, the doctor may recommend temporarily stopping the medication or adjusting the dose to ensure patient safety.

Digestive side effects are common reactions during the use of capmatinib, including nausea, vomiting, diarrhea, constipation and decreased appetite. People with mild symptoms can find relief by eating smaller meals more frequently, avoiding irritating foods, and replenishing fluids. For moderate or severe gastrointestinal discomfort, doctors can prescribe antiemetics, antidiarrheals or rehydration treatment according to the situation. It is also recommended to regularly monitor weight and electrolyte levels to prevent dehydration and electrolyte imbalance. In addition, some patients may develop stomatitis, dry mouth, or oral ulcers, which can be relieved by oral hygiene, salt water gargling, or topical medications.

Systemic symptoms such as fatigue, mild edema, and muscle or joint pain are also common. For fatigue and muscle soreness, patients can relieve it through moderate rest, light aerobic exercise and regular work and rest, while ensuring protein and vitamin intake. Edema manifests as mild swelling of the lower limbs or swelling of the eyelids, which can be controlled by elevating the lower limbs, limiting salt intake, or using diuretics under the guidance of a doctor. Skin reactions such as rash and itching can also be relieved with anti-allergic drugs or topical ointments under the advice of a doctor. In addition, a small number of patients may experience increased blood pressure, abnormal heart rhythm or pulmonary symptoms. During the medication period, blood pressure, electrocardiogram and imaging indicators should be monitored regularly to detect potential risks in a timely manner.

The core principles for scientifically handling the side effects of capmatinib are early detection, early intervention and individualized management. Patients should establish a self-monitoring system during the medication period, including recording weight changes, blood pressure, skin conditions and any symptoms of discomfort, and reviewing blood routine, liver and kidney function and electrocardiogram regularly. Once obvious abnormalities occur, you should contact your doctor immediately to avoid stopping the medication on your own or adjusting the dosage at will. Mild and moderate side effects can usually be alleviated through lifestyle intervention, dietary adjustment, and symptomatic treatment; for moderate to severe symptoms or symptoms that affect quality of life, doctors may take measures such as dose reduction, temporary drug suspension, or combined adjuvant treatment. At the same time, maintaining good living habits, such as adequate sleep, a balanced diet, moderate exercise, and avoiding infections, can effectively reduce the frequency and severity of side effects.

In short, although capmatinib is METExon14Skipping mutation positiveNSCLC patients have significant efficacy, but its side effects cannot be ignored. Through scientific monitoring, timely intervention and individualized management, most blood, digestive and systemic symptoms can be effectively controlled, thereby ensuring that patients can complete treatment safely and continuously, and improving the overall efficacy and quality of life. Patients and their families should work closely with their attending doctors to jointly develop a reasonable side effect management plan to make targeted therapy both safe and efficient.

Reference link:https://www.drugs.com